# Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

> **NCT06874946** · PHASE1,PHASE2 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- T - Cell Lymphoma
- PTCL

## Interventions

- **BIOLOGICAL:** CD5-targeted CAR-T cells

## Key facts

- **NCT ID:** NCT06874946
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-14
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06874946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06874946, "Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06874946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*